全光谱快速临床基因组测序提高中国新生儿基因组计划中危重婴儿的诊断率和临床结局
本研究为前瞻性研究,纳入中国新生儿基因组计划13家成员医院、10个省的202例危重婴儿(出生至13月龄),同时进行仅先证者临床外显子测序和三联快速基因组测序。三联快速基因组测序诊断率36.6%(95%CI 30.1-43.7%)高于仅先证者临床外显子测序20.3%(95%CI 15.1-26.6%),p=0.0004;中位周转时间7天快于20天(p<2.2×10-16)。宏基因组分析在6例脓毒症症状婴儿中检出致病或可能致病微生物并指导抗生素策略。16例(21.6%)因诊断改变临床管理,24例(32.4%)转诊至新亚专科。
要点
- 在202例危重婴儿中,三联快速基因组测序诊断率36.6%(95%CI 30.1-43.7%),高于仅先证者临床外显子测序的20.3%(95%CI 15.1-26.6%),p=0.0004。
- 三联快速基因组测序中位周转时间7天,快于仅先证者临床外显子测序的20天(p<2.2×10-16)。
- 最常见表型为神经肌肉(45%)、呼吸(22%)和免疫/感染(18%)。
- 宏基因组分析在6例有脓毒症症状的婴儿中检出致病或可能致病微生物,并指导抗生素治疗策略。
- 16例(21.6%)在三联快速基因组测序诊断后临床管理发生改变,24例(32.4%)转诊至新的亚专科。
适用人群与场景
- 危重婴儿,从出生至13月龄,依据纳入标准入组(如中枢神经系统异常、复杂先天性心脏病、代谢病证据、反复严重感染、疑似免疫缺陷和多发畸形)。
- 研究在10个省的13家中国新生儿基因组计划成员医院进行。
研究设计与关键结果
- 研究类型为前瞻性研究,纳入202例危重婴儿,来自13家医院、10个省,研究时间为2019年4月至2019年12月。
- 最常见表型为神经肌肉(45%)、呼吸(22%)和免疫/感染(18%)。
- 三联快速基因组测序诊断率36.6%(95%CI 30.1-43.7%),仅先证者临床外显子测序诊断率20.3%(95%CI 15.1-26.6%),p=0.0004。
- 三联快速基因组测序中位周转时间7天,仅先证者临床外显子测序中位周转时间20天,p<2.2×10-16。
- 宏基因组分析在6例有脓毒症症状的婴儿中检出致病或可能致病微生物,并指导抗生素治疗策略。
- 16例(21.6%)在三联快速基因组测序诊断后临床管理发生改变,24例(32.4%)转诊至新的亚专科。
证据类型、等级与局限
- 证据类型:前瞻性研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,与仅先证者临床外显子测序相比,三联快速基因组测序在危重婴儿队列中提供了更高的诊断率和更短的周转时间。
- 作者认为,精准快速的分子诊断可以改变医疗管理并对患者结局产生积极影响。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: To determine the diagnostic and clinical utility of trio-rapid genome sequencing in critically ill infants.
DESIGN: In this prospective study, samples from critically ill infants were analyzed using both proband-only clinical exome sequencing and trio-rapid genome sequencing (proband and biological parents). The study occurred between April 2019 and December 2019.
SETTING: Thirteen member hospitals of the China Neonatal Genomes Project spanning 10 provinces were involved.
PARTICIPANTS: Critically ill infants (n = 202), from birth up until 13 months of life were enrolled based on eligibility criteria (e.g., CNS anomaly, complex congenital heart disease, evidence of metabolic disease, recurrent severe infection, suspected immune deficiency, and multiple malformations).
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: Of the 202 participants, neuromuscular (45%), respiratory (22%), and immunologic/infectious (18%) were the most commonly observed phenotypes. The diagnostic yield of trio-rapid genome sequencing was higher than that of proband-only clinical exome sequencing (36.6% [95% CI, 30.1-43.7%] vs 20.3% [95% CI, 15.1-26.6%], respectively; p = 0.0004), and the average turnaround time for trio-rapid genome sequencing (median: 7 d) was faster than that of proband-only clinical exome sequencing (median: 20 d) (p < 2.2 × 10-16). The metagenomic analysis identified pathogenic or likely pathogenic microbes in six infants with symptoms of sepsis, and these results guided the antibiotic treatment strategy. Sixteen infants (21.6%) experienced a change in clinical management following trio-rapid genome sequencing diagnosis, and 24 infants (32.4%) were referred to a new subspecialist.
CONCLUSIONS: Trio-rapid genome sequencing provided higher diagnostic yield in a shorter period of time in this cohort of critically ill infants compared with proband-only clinical exome sequencing. Precise and fast molecular diagnosis can alter medical management and positively impact patient outcomes.
参考来源
- Wu B, Kang W, Wang Y, et al. Application of Full-Spectrum Rapid Clinical Genome Sequencing Improves Diagnostic Rate and Clinical Outcomes in Critically Ill Infants in the China Neonatal Genomes Project. Crit Care Med. 2021. PMID: 33935161. doi:10.1097/CCM.0000000000005052
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。